All the Drug Class Drugs
Interleukin Inhibitor. Secukinumab 150 mg. VIAL(pwdr. for sol. for inj.): 1×6ml.
PRE FILL. PEN/SYR (sol. for inj.): 1, 2×1ml Plaque psorias.: 300 mg by SC inj. with init. dosing at Weeks 0, 1, 2, 3 and 4, follow. by mnthly. mainten. dosing. Each 300 mg dose is given as two SC inj. of 150 mg. Psoriat. arthrit.: For pts. with concom. moder.-sev. plaque psorias. or who are anti-TNFα inadeq. responders (IR): 300 mg by SC inj. with init. dosing at Weeks 0, 1, 2, 3 and 4, follow. by mnthly. mainten. dosing. Each 300 mg dose is given as two SC inj. of 150 mg.
For other pts.: dose is 150 mg by SC inj. with init. dosing at Weeks 0, 1, 2, 3 and 4, follow. by monthly mainten. dosing. Ankylos. spondylit.: 150 mg by SC inj. with init. dosing at Weeks 0, 1, 2, 3 and 4, follow. by mnthly. mainten. dosing.
For all of the above indications, usually achieved within 16 wks. of tmt. Consider. should be given to discont. tmt. in pts. who have shown no response by 16 wks. of tmt. Some pts. with an init. partial response may subseq. improve with continued tmt. beyond 16 wks.
Plaque psorias.: Tmt. of moder.- sev. plaque psorias. in adult. who are candidates for system. ther.
Psoriat. arthrit.: Alone or in comb. with methotrexate (MTX): tmt. of active psoriat. arthrit. in adult pts. when the response to previous dis.-modif. anti-rheumatic drug (DMARD) ther. has been inadeq.
Ankylosing spondylitis: Tmt. of active ankylos. spondylitis in adult. who have responded inadeq. to convent. ther.
C/I: Severe hypersens. Clinical. important, active infec. (e.g. active tuberculosis).
Interleukin Inhibitor. Tildrakizumab 100 mg / 1 ml. PREFILL. SYRINGE:100 mg 100 mg SC inj. at wks. 0, and 4, every 12 wks. thereafter.
Tmt. of adult. with mod.-sev. plaque psoriasis who are candidates for syst. ther. or photother.
C/I: Hypersens. Clinic. import. active infect., e.g. active tubercul.
Interleukin Inhibitor, Monoclonal Antibody. Mirikizumab 100 mg/ml. Pre-filled syr./pen with sol. for SC inj. 2X 100 mg/ml and 200 mg/2 ml
Induction dose: 300 mg by IV inf. for at least 30 minutes at weeks 0, 4 and 8.
Maint. dose: 200 mg (i.e. two pre-filled syringes or two pre-filled pens) by SC inject. every 4 weeks after induction.
Tmt of adults with moder. to sev. active ulcerative colitis who have had an inadeq. response with, lost response to, or were intol. to either convent. ther. or a biologic tmt.
Tmt. of adults with moder. to sever. active Crohn's dis. who have had an inadeq. response with, lost response to, or were intol. to either conventional ther. or a biologic tmt.
C/I: Hypersens. Clin. important active infect. (active TB).
Interleukin Inhibitor, Monoclonal Antibody. Mirikizumab 20 mg/ml. VIAL , conc. for sol. for inf. 1 X. 300 mg/15 ml
Induction dose: 300 mg by IV inf. for at least 30 minutes at weeks 0, 4 and 8.
Maint. dose: 200 mg (i.e. two pre-filled syringes with 100 mg each or two pre-filled pens) by SC inject. every 4 weeks after induction
Tmt of adults with moder. to sev. active ulcerative colitis who have had an inadeq. response with, lost response to, or were intol. to either convent. ther. or a biologic tmt. Tmt. of adults with moder. to sever. active Crohn's dis.
who have had an inadeq. response with, lost response to, or were intol. to either conventional ther. or a biologic tmt.
C/I: Hypersens. Clinic, important active infect. (active TB).
Interleukin Inhibitor, Monoclonal Antibody. Risankizumab 150 mg. Pre-fil. syr/pen with sol. for SC inj. with 150 mg
For mod. to sev. plaque psor. in adlts. who are candidates for syst. ther. Alone or in comb. with methotrexate (MTX) for act. psoriatic arthr. in adlts who had an inadeq. resp.or who have intol. to one or more dis.-modifying antirheum. drugs (DMARDs). Recom. dose 150 mg admin. at week 0, week 4, and every 12 weeks thereafter one 150 mg pre-filled pen or pre-filled syr. inject).
C/I: Hypersens. Clinic. import. act. infect. (e.g. act.TB)
Interleukin Inhibitor, Monoclonal Antibody. Risankizumab 180 mg, 360 mg, 600 mg. Cartr. Sol. for inj. 1 X 180/360 mg
Vial. Conc. for sol. for inf. 1 X 600 mg/10 ml
For Chron dis.: 600 mg by IV inf. at week 0, week 4, and week 8, followed by 360 mg by SC inject. at week 12, and every 8 weeks thereafter.
For Ulcer. col.: induction dose 1200 mg by IV inf. at week 0, week 4, and week 8. Starting at week 12 and every 8 weeks thereafter, maint. dose is based on individual ptt. presentation.
360 mg and 600 mg: Crohn’s disease in pts > 16 years with mod. to sev. active CD who have had an inadequate response to, lost response to, or were intol. to conventional ther. or a biologic ther., or if such ther. are not advisable.
180, 360 mg and 600 mg: Ulcerative colitis in adults with mod. to sev. active UC who have had an inadequate response to, lost response to, or were intol. to conventional ther. or a biologic ther.
C/I: Hypersens./Clin. important active infect. (e.g. active TB).
